arrow
M

Manuel Carção

university of toronto
H指数:42
被引数:7,696

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sirolimus is effective for paediatric Evans syndrome and secondary autoimmune cytopenias: A retrospective cohort study

西罗莫司对儿童埃文斯综合征和继发性自身免疫性血细胞减少症有效:一项回顾性队列研究

2026-09-060
OAAI
The MAPTO survey: Worldwide Approaches on Unmasking Factor VIII Inhibitors in Children with Emicizumab Treatment: Communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders
2026-02-030
OAAI
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025

《WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025》

2025-10-250
OAAI
Large deletions in the F8 gene predict immune tolerance induction failure in people with severe hemophilia A

F8基因中的大片段缺失可预测严重血友病A患者免疫耐受诱导失败。

2025-10-100
OAAI
Predictors of ITI success in 231 children with Severe hemophilia A with high titer inhibitors – lessons learned from the PedNet prospective cohort study

231例高滴度抑制物的严重A型血友病儿童ITI成功预测因素——来自PedNet前瞻性队列研究的经验教训

2025-07-220
PRE
Cerebral sinus venous thrombosis in a child with Québec platelet disorder with high-resolution intracellular localization of urokinase in platelets

一名患有魁北克血小板失调症(Québec platelet disorder)的儿童出现脑静脉窦血栓形成,并伴有尿激酶在血小板内的亚细胞高分辨率定位。

2025-07-010
OAAI
Evaluation of Point-of-Care Ultrasound in Paediatric Haemophilic Arthropathy: A Prospective Comparative Study With Comprehensive Ultrasound and MRI

床旁超声在儿童血友病性关节病中的评估:一项与全面超声和MRI的前瞻性比较研究

2025-05-190
PRE
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors

使用epacog beta (rFVIIa) 进行出血治疗可使患有a型或b型血友病的成人和青少年患者的再出血发生率降低

2024-12-150
OA
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
2024-12-090
PRE
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal
2024-12-060
PREAI
Real-World Experience of Switching to Prophylactic Efanesoctocog Alfa in Patients with Moderate and Severe Hemophilia a: An Analysis of the Adelphi Hemophilia Wave III Disease Specific Programme

中重度血友病A患者转为预防性使用Efanesoctocog Alfa的真实世界经验:一项对Adelphi血友病III期疾病特异性项目(Hemophilia Wave III Disease Specific Programme)的分析

BLOOD
IF23.1
2024-11-050
PRE
Prediction of the chance of successful immune tolerance induction in persons with severe hemophilia A and inhibitors: a clinical prediction model

预测严重血友病A和抑制剂患者成功诱导免疫耐受的机会: 临床预测模型

2024-10-010
OAAI
Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A
2024-07-185
PRE